|
Mylan Settles Provigil Dispute, Allowed to Launch in August
Mylan can commence U.S. generic sales of the sleep disorder drug Provigil on Aug. 10, before the end of Teva’s 180-day marketing exclusivity period, under a settlement reached by the two companies.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives